Maltoni et al. [33] investigated the role of cfDI as a prognostic biomarker using different targets such as BCAS 1 266/129, MYC 264/128, and PIK3CA 274/129 in relapsed BC, non-relapsed BC, and HC. This evidence concerns the gene PIK3CA and breast cancer.